Search - tctmd.com

Displaying 201 - 220 of 222

Sort: Relevancy | Date

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

News Daily News

When Problems Arise With Prosthetic Heart Valves, Multimodality Imaging Is Needed, Say European Guidelines

Todd Neale

May 06, 2016

News Daily News

Sluggish CMS Reimbursement Lags Cardiac Device Approvals: Should Value Endpoints be Added to Trials?

Yael L. Maxwell

May 02, 2016

News Daily News

Los Lentos Reembolsos de los CMS Lastran las Aprobaciones de Dispositivos Cardíacos: ¿Deberían de Incorporarse a los Ensayos Puntos Finales sobre el Valor?

Yael L. Maxwell

May 02, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

News Daily News

Expert Consensus Highlights Needs of Cancer Patients in the Cath Lab and Beyond

L.A. McKeown

January 12, 2016

News Daily News

MVARC Document Offers Template for Mitral Valve Therapeutics Research

Todd Neale

July 16, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Daily News

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

July 07, 2015

News Daily News

CoreValve在高风险患者中的生存益处到2年时依然持续存在

July 07, 2015

News Industry News

First North American Trial Results Reinforce the Safety and Hemodynamic Performance of Sorin’s Solo Smart Pericardial Aortic Valve

June 24, 2015

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

July 25, 2013

News Daily News

European TAVR Usage Tied to Economics, Reimbursement

Yael L. Maxwell

July 12, 2013

Presentation TCT 2012

Hemodynamics and Interactive Calculations for Aortic Stenosis Using the "John Madden" Telestrator

Presenter: Tim Lapp

October 22, 2012

Advertisement

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

When Problems Arise With Prosthetic Heart Valves, Multimodality Imaging Is Needed, Say European Guidelines

Sluggish CMS Reimbursement Lags Cardiac Device Approvals: Should Value Endpoints be Added to Trials?

Los Lentos Reembolsos de los CMS Lastran las Aprobaciones de Dispositivos Cardíacos: ¿Deberían de Incorporarse a los Ensayos Puntos Finales sobre el Valor?

TCTMD’s Top 10 Most Popular Stories for April 2016

Expert Consensus Highlights Needs of Cancer Patients in the Cath Lab and Beyond

MVARC Document Offers Template for Mitral Valve Therapeutics Research

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

CoreValve在高风险患者中的生存益处到2年时依然持续存在

First North American Trial Results Reinforce the Safety and Hemodynamic Performance of Sorin’s Solo Smart Pericardial Aortic Valve

Innovation in Intervention: Perspectives from Industry

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

European TAVR Usage Tied to Economics, Reimbursement

Hemodynamics and Interactive Calculations for Aortic Stenosis Using the "John Madden" Telestrator

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content